Liver Cancer can be defeated: Tekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial
Hepatocellular carcinoma (HCC), or liver cancer is the third leading cause of cancer related deaths worldwide. The new Phase I human clinical trial for the drug TKM-PLK1 that prevents the tumor cell from completing cell division could give a new hope, strength and resilience to the patients are fighting with this fatal disease.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics has started a clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1 (PLK1), a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
To examine the safety, tolerability and pharmacokinetics of TKM-PLK1, this open label, dose-escalation study, Phase 1 clinical trial will be conducted at three medical centers in the United States. This study will be conducted on patients with advanced solid tumors. This trial has an accrual goal of 52 patients per trial. This clinical trial will also measure tumor response as well as the pharmacodynamic effects of TKM-PLK1 in patients providing biopsies.
In preclinical animal studies, TKM-PLK1 has been shown to selectively kill cancer cells, while sparing normal cells in healthy tissue.
RNAi therapeutics have the potential to treat a broad number of human diseases and for this medicine the company has received the 2006 Nobel Prize for Physiology or Medicine. Tekmira’s LNP technology delivers siRNAs with high efficiency and it is effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.
If you are interested in participating in a clinical trial of liver cancer, you can find trials near you.